Maxonis Technology & Product
Our goal is to address the unmet medical needs of individuals suffering from spinal cord injuries (SCIs), peripheral nerve injuries (PNIs), and other nerve traumas
such as traumatic brain injury (TBI).
Our primary focus is on developing and commercializing our patented AGRG hydrogel technology, which promotes nerve regeneration.
Bridging nerve gaps with nerve regeneration technologies
Preclinical trials demonstrated the ability of the AGRG to regenerate severely nerve injuries and bridge nerve gaps.
The AGRG technology is the result of 15 years of award-winning collaborative research by Tel Aviv University and Tel Aviv Sourasky Medical Center testing multiple materials and combinations.
AGRG has a strong patent portfolio comprised of 5 patent families.
2008
IP provisional - patent #1
2017
Research supported by Baxter, IP provisional - patent #2
2018
IP provisional patent #3
2020
IP provisional - patent #4 + #5
November 2022
Plenty licensed AGRG technology from Ichilov/TAU
February 2023
Maxonis is the new name. Fund raising of 4M$ completed.
2023 workplan. 2 feasibility studies launched, PNI & SCI
November 2023
Discussions with the FDA & CE. Workplan 2024-2025
January 2024
First successful results in SCI study. 2024 workplan launched
2024 Development Pipeline
Maxonis is advancing a robust pipeline of innovative therapies designed to revolutionize nerve regeneration and repair, targeting critical unmet needs in spinal cord, peripheral nerve and traumatic brain injuries
